Flight data analysis and further development of variable-conductance heat pipes

Continuing efforts in large gains in heat-pipe performance are reported. It was found that gas-controlled variable-conductance heat pipes can perform reliably for long periods in space and effectively provide temperature stabilization for spacecraft electronics. A solution was formulated that allows the control gas to vent through arterial heat-pipe walls, thus eliminating the problem of arterial failure under load, due to trace impurities of noncondensable gas trapped in an arterial bubble during priming. This solution functions well in zero gravity. Another solution was found that allows priming at a much lower fluid charge. A heat pipe with high capacity, with close temperature control of the heat source and independent of large variations in sink temperature was fabricated

An investigation of the thermal radiation properties of certain spacecraft materials Final report

Thermal radiation analysis for anodized aluminum - anodizing process evaluation for optimum properties under space conditions for spacecraft temperature contro

Vapor-modulated heat pipe report. Flight data analysis and further development of variable-conductance heat pipes

The design and testing of a heat pipe for spacecraft application is presented. The application in mind calls for heat loads up to 20 watts, a set-point temperature of 294K, and a sink that varies from -220K to nearly as high as the set-point. The overall heat pipe length is 137 cm. Two basically different mechanisms of achieving variable conductance in the pipe by vapor-flow throttling were studied. In one, the thermal resistance between the heat source and sink is due to a saturation-temperature drop corresponding to the vapor-pressure drop developed across the valve. In the other, the pressure difference across the valve induces capillary groove and wick dry out in an evaporation region, and thus results in an increased thermal resistance. This mechanism was selected for fabrication and testing. The pipe is a stainless-steel/methanol two-heat-pipe system. Results are presented and discussed. Engineering drawings and specifications of the pipe are shown

Heat Pipe Materials Compatibility

An experimental program to evaluate noncondensable gas generation in ammonia heat pipes was completed. A total of 37 heat pipes made of aluminum, stainless steel and combinations of these materials were processed by various techniques, operated at different temperatures and tested at low temperature to quantitatively determine gas generation rates. In order of increasing stability are aluminum/stainless combination, all aluminum and all stainless heat pipes. One interesting result is the identification of intentionally introduced water in the ammonia during a reflux step as a means of surface passivation to reduce gas generation in stainless-steel/aluminum heat pipes

Positional Differences in Training Load During Matches and Practices in Collegiate Female Soccer Players

Click the PDF icon to download the abstract

Oxytocin in the Circadian Timing of Birth

BACKGROUND: The molecular components determining the timing for birth remain an incompletely characterized aspect of reproduction, with important conceptual and therapeutic ramifications for management of preterm, post-term and arrested labor. METHODOLOGY/PRINCIPAL FINDINGS: To test the hypothesis that oxytocin mediates circadian regulation of birth, we evaluated parturition timing following shifts in light cycles in oxytocin (OT)-deficient mice. We find that, in contrast to wild type mice that do not shift the timing of birth following a 6-h advance or delay in the light cycle, OT-deficient mice delivered at random times of day. Moreover, shifts in the light-dark cycle of gravid wild type mice have little impact on the pattern of circadian oxytocin release. CONCLUSIONS/SIGNIFICANCE: Our results demonstrate oxytocin plays a critical role in minimizing labor disruption due to circadian clock resetting

Potential role of ticks as vectors of bluetongue virus

When the first outbreak of bluetongue virus serotype 8 (BTV8) was recorded in North-West Europe in August 2006 and renewed outbreaks occurred in the summer of 2007 and again in 2008, the question was raised how the virus survived the winter. Since most adult Culicoides vector midges are assumed not to survive the northern European winter, and transovarial transmission in Culicoides is not recorded, we examined the potential vector role of ixodid and argasid ticks for bluetongue virus. Four species of ixodid ticks (Ixodes ricinus, Ixodes hexagonus, Dermacentor reticulatus and Rhipicephalus bursa) and one soft tick species, Ornithodoros savignyi, ingested BTV8-containing blood either through capillary feeding or by feeding on artificial membranes. The virus was taken up by the ticks and was found to pass through the gut barrier and spread via the haemolymph into the salivary glands, ovaries and testes, as demonstrated by real-time reverse transcriptase PCR (PCR-test). BTV8 was detected in various tissues of ixodid ticks for up to 21 days post feeding and in Ornithodoros ticks for up to 26 days. It was found after moulting in adult Ixodes hexagonus and was also able to pass through the ovaries into the eggs of an Ornithodoros savignyi tick. This study demonstrates that ticks can become infected with bluetongue virus serotype 8. The transstadial passage in hard ticks and transovarial passage in soft ticks suggest that ticks have potential vectorial capacity for bluetongue virus. Further studies are required to investigate transmission from infected ticks to domestic livestock. This route of transmission could provide an additional clue in the unresolved mystery of the epidemiology of Bluetongue in Europe by considering ticks as a potential overwintering mechanism for bluetongue virus

Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial

Single-agent therapy with Docetaxel or Pemetrexed is the current therapy of choice for second-line treatment in advanced non-small-cell lung cancer (NSCLC). The role of older agents was underattended over the last years. This study presents the combination of Mitomycin C and Vinorelbine in pretreated patients. Forty-two patients (stage IIIB and IV, pretreated with platinum-based chemotherapy) received 8 mg m−2 Mitomycin C on day 1 and 25 mg m−2 Vinorelbine on days 1 and 8 of a 28-day cycle. End points were objective tumour response, survival, and toxicity. Additionally, quality of life (QoL) was assessed. Five patients (11.9 %) achieved partial responses and 13 patients (31.9%) stable disease. Progression-free survival was 16 weeks. The median overall survival was 8.5 month. Eleven patients (26.2 %) suffered from grade 3 or 4 neutropenia and four patients (9.52%) from grade 3 or 4 anaemia. Evaluation of QoL showed that some items ameliorated during therapy. The therapeutic concept including Mitomycin C and Vinorelbine offers an efficacious and well-tolerated regimen, with relatively low toxicity. Objective response and survival data correlate with other second-line studies using different medication. As costs of Mitomycin C and Vinorelbine are lower compared with current drugs of choice, this regimen is likely to be cost-saving

Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02)

To evaluate the efficacy and toxicity of the sequential nonplatinum combination chemotherapy consisting of gemcitabine (GEM) and vinorelbine (VNR) followed by docetaxel (DOC) in patients with advanced non-small-cell lung cancer (NSCLC), we conducted the multiinstitutional phase II study. A total of 44 chemotherapy-naive patients with advanced NSCLC were treated with GEM 1000 mg m−2 and VNR 25 mg m−2 intravenously on days 1 and 8 every 3 weeks for three cycles. DOC 60 mg m−2 was then administrated intravenously at 3-week intervals for three cycles. Patients were evaluated for response and toxicity with each cycle of the treatment. The major objective response rate was 47.7% (95% confidence interval (CI), 33.8–62.1%). Median survival time (MST) was 15.7 months and 1-year survival rate was 59%. In the GEM/VNR cycle, grade 3/4 neutropenia occurred in 36.3%, grade 3/4 anaemia in two patients (4.5%) and grade 3 thrombocytopenia in one patient (2.3%). Grade 3 pneumonitis occurred in two patients (4.5%) in GEM/VNR cycles. In the DOC cycles, grade 3/4 neutropenia occurred in 39.4% but no patient experienced grade 3/4 anaemia or thrombocytopenia. Of the 44 eligible patients, 33 patients completed three cycles of GEM/VNR and 22 patients completed six cycles of planned chemotherapy (three cycles of GEM/VNR followed by three cycles of DOC). The sequential triplet nonplatinum chemotherapy consisted of GEM/VNR followed by DOC, and was very active and well tolerated. This study forms the basis for an ongoing phase III trial that compares this nonplatinum triplet and standard platinum doublet combination (carboplatin/paclitaxel)